



July 29, 2014

Supernus to Host Second Quarter 2014 Earnings Conference Call

ROCKVILLE, Md., July 29, 2014 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company expects to report the financial results for the second quarter 2014 after 5:00 pm ET on Monday, August 11, 2014.

Jack Khattar, President and Chief Executive Officer and Greg Patrick, Chief Financial Officer will host a conference call to discuss second quarter 2014 financial results on Tuesday, August 12, 2014 at 9:00 AM Eastern Time.

A live webcast will be available at www.supernus.com. Following the live call, a replay will be available on the Company's website under 'Investor Info'. The webcast will be archived on the Company's website for 30 business days following the live call.

Please refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior to the start of the call.

Conference dial-in: 877-288-1043

International dial-in: 970-315-0267

Conference ID: 75364090

Conference Call Name: Supernus Pharmaceuticals 2Q 2014 Earnings Conference Call

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR™ (extended-release topiramate). The Company is also developing several product candidates in psychiatry to address large market opportunities in ADHD, including ADHD patients with impulsive aggression. These product candidates include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.

CONTACT: Supernus Pharmaceuticals, Inc., 301-838-2591

Jack A. Khattar, President and CEO

Gregory S. Patrick, Vice President and CFO

or

Investor Contact:

Cockrell Group, 877-889-1972

investorrelations@thecockrellgroup.com

cockrellgroup.com



Source: Supernus Pharmaceuticals, Inc.

News Provided by Acquire Media